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Abstract The risk of future symptomatic intracerebral
haemorrhage (sICH) remains uncertain in patients with
acute convexity subarachnoid haemorrhage (cSAH) asso-
ciated with suspected cerebral amyloid angiopathy (CAA).
We assessed the risk of future sICH in patients presenting
to our comprehensive stroke service with acute non-trau-
matic cSAH due to suspected CAA, between 2011 and
2016. We conducted a systematic search and pooled
analysis including our cohort and other published studies
including similar cohorts. Our hospital cohort included 20
patients (mean age 69 years; 60% male); 12 (60%) had
probable CAA, and 6 (30%) had possible CAA according
to the modified Boston criteria; two did not meet CAA
criteria because of age\55 years, but were judged likely to
be due to CAA. Fourteen patients (70%) had cortical
superficial siderosis; 12 (60%) had cerebral microbleeds.
Over a mean follow-up period of 19 months, 2 patients
(9%) suffered sICH, both with probable CAA (annual sICH
risk for probable CAA 8%). In a pooled analysis including
our cohort and eight other studies (n = 172), the overall
sICH rate per patient-year was 16% (95% CI 11–24%). In
those with probable CAA (n = 104), the sICH rate per
patient-year was 19% (95% CI 13–27%), compared to 7%
(95% CI 3–15%) for those without probable CAA
(n = 72). Patients with acute cSAH associated with sus-
pected CAA are at high risk of future sICH (16% per
patient-year); probable CAA might carry the highest risk.
Keywords Non-traumatic convexity/convexial/cortical
subarachnoid haemorrhage  Intracerebral haemorrhage 
Cerebral amyloid angiopathy  Superficial siderosis  Stroke
Introduction
Non-traumatic acute convexity subarachnoid haemorrhage
(cSAH)—also known as acute cortical subarachnoid
haemorrahge—is confined to the subarachnoid space over
the cortical hemispheric convexities of the brain, and does
not extend into the parenchyma, sylvian fissures, ventricles,
or basal cisterns [1]. The aetiology and symptoms of cSAH
are diverse, but have been classified by age of presentation
[1–7]; in younger patients (usually\60 years), cSAH often
occurs in association with reversible cerebral vasocon-
striction syndrome (RCVS), with recurrent thunderclap
headache as the predominant presenting symptom [8].
RCVS generally has a favourable outcome with very low
recurrence risk, although in the acute phase both ischaemic
stroke and intracerebral haemorrhage (ICH) can occur in a
minority of patients [9]. By contrast, in older patients,
cSAH is associated with cerebral amyloid angiopathy
(CAA) [10], often presenting with transient focal neuro-
logical episodes (TFNE), often consisting of unilateral
spreading sensory or motor symptoms. In CAA there is a
substantial risk of recurrent symptomatic ICH (sICH) after
presentation with ICH [11], but knowledge about ICH risk
following cSAH in patients with suspected CAA is limited,
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comprising only small cohort studies which individually
contain very few clinical outcome events. A pooled meta-
analysis of event rates from multiple prospective cohort
studies allows a more precise estimate of sICH risk than is
available from any individual study. This information is
important in guiding clinical decision making with regard
to prognosis and antithrombotic treatment, a common
management dilemma in older patients at risk of vaso-oc-
clusive events, for example those with atrial fibrillation or
ischaemic heart disease.
We therefore investigated the risk of sICH following
cSAH in: (1) a cohort of patients from our comprehensive
stroke service presenting with acute symptomatic cSAH
due to suspected CAA and (2) a pooled analysis which
included our cohort and all other available published data
on cSAH in suspected CAA cohorts.
Materials and methods
Data collection
Hospital based cohort study
We retrospectively searched prospective radiological and
clinical databases of patients who were assessed in our
specialist comprehensive stroke service (University Col-
lege Hospital and the National Hospital for Neurology and
Neurosurgery, Queen Square) between 2011–2016 and
diagnosed with suspected CAA; our search terms were
‘‘convexity subarachnoid haemorrhage’’ and ‘‘cortical
subarachnoid haemorrhage’’. Our inclusion criteria were:
acute symptomatic cSAH visualised on CT or MRI, with
exclusion of non-CAA causes of cSAH (including RCVS,
cerebral venous sinus thrombosis, aneurysmal SAH or
traumatic SAH), and the availability of follow-up sICH
data. Information on patient demographics, risk factor
profile, history of previous ICH, and follow up data was
obtained from electronic medical records which clearly
confirmed the absence or presence of new symptoms or
signs of stroke. Our outcome of interest was the presence
of sICH confirmed on neuroimaging (CT or MRI) during
the follow-up period. Markers of cerebral small vessel
disease were rated by a postgraduate clinical neurology
trainee PhD student (DW) trained by a consultant vascular
neuro-radiologist with reproducibility against other
observers confirmed in previous projects (with similar
cohorts and imaging acquisition), consistently obtaining
Kappa values between 0.6 and 0.8 for cerebral microb-
leeds (CMBs), cortical superficial siderosis, MRI-visible
enlarged perivascular spaces (EPVS) and white matter
hyperintensities. Cerebral microbleeds were rated on T2*-
weighted or susceptibility-weighted imaging using the
MARS scale [12], white matter hyperintensities were
rated on FLAIR sequences using the simplified Fazekas
scale [13], and EPVS were rated on T2-weighted
sequences using a validated four point rating scale [14].
Cortical superficial siderosis was rated using as focal or
disseminated using a previously developed scale [15]
(siderosis was not rated if it corresponded to the acute
cSAH) according to standardised criteria [16]. Brain
imaging was also reviewed to assess whether or not each
patient met the modified Boston diagnostic criteria for
probable or possible CAA [15].
Systematic review and pooled meta-analysis
Two authors (DW and ICH) searched Medline for cohort
studies of cSAH using key words ‘‘convex* adj4 sub-
arachnoid’’ OR cortical adj4 subarachnoid OR sulc* adj4
subarachnoid on the 20/05/2016, in addition to the refer-
ence lists. We did not limit the search terms to any lan-
guage or dates. Only studies including participants with
suspected CAA with no other obvious cause for their
cSAH, and at least 6 months of follow-up data, were
included. The two authors reviewed all papers and inde-
pendently extracted the following information: population
from which patients were drawn, number of patients,
mean follow-up time, and outcome events (sICH and
death). In two studies, follow up data were given as
median values; these were converted to mean values using
a validated method [16–18]. Our cohort study is reported
according to the STROBE guidelines, and the pooled-
analysis was conducted according to PRISMA guidelines
[19].
Statistical analysis
We calculated the pooled risk of sICH for patients with
cSAH and suspected CAA using a mixed effects Poisson
model to account for studies with no ICH outcomes. We
then calculated the risks of sICH in patients who fulfilled
the Boston criteria for probable CAA, and for those who
did not fulfil these criteria. Meta-analysis was used to
create forest plots for patients fulfilling probable CAA and
for those who did not fulfil this criteria. Rates were cal-
culated per patient year and exact Poisson 95% confidence
intervals were calculated for each study. Statistical analysis
was performed using STATA 13 (StataCorp. 2011; Stata
Statistical Software: Release 13; College Station, TX:
StataCorp LP).
Ethical approval
Data collection was approved as a Service Evaluation in
the Comprehensive Stroke Service, University College
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London Hospitals NHS Foundation Trust. The study
was also approved by an NHS Health Research
Authority Research Ethics Committee (reference:
15/LO/1443).
Results
Hospital-based cohort study
We identified 27 patients with cSAH between January 2011
and February 2016. After excluding those diagnosed with
causes other than suspected CAA (RCVS or aneurysmal
cSAH) and cases where cSAH was diagnosed incidentally
without clinical suspicion of CAA, we included 20
patients. The median age was 69 years and 60% were male.
The demographic and clinical characteristics of the cohort
are shown in Table 1. Of the 20 patients, 12 had probable
CAA according to the modified Boston criteria [15], while
6 had possible CAA. Two patients, aged 50 and 53, were
still considered suspected to have CAA despite being less
than 55 years old.
Cerebral microbleeds (CMBs) were present in 12 of 20
(60%) of patients, with a median of 1 (IQR 0–4). All CMBs
were lobar. Cortical superficial siderosis (cSS) was present
in 19 of 20 (95%) of patients; this was outside the region of
their acute cSAH in 15 of 20 patients (75%) and, in these
cases, was disseminated ([3 sulci) in 13 of 15 patients
(87%). Severe white matter hyperintensities (defined as
either simplified Fazekas C2 in periventricular or deep
white matter) were present in 8 of the 20 patients (40%).
MRI-visible perivascular spaces of moderate or severe
grade (grades 3 or 4) were present in the centrum semio-
vale in 9 of 20 patients (45%).
All but one of our 20 patients had transient focal neu-
rological episodes (TFNE) as their presenting symptom
(one had headache and loss of consciousness); 8 (40%) had
only negative symptoms (e.g. weakness, numbness), while
12 (60%) had positive symptoms (e.g. paraesthesias).
Three of the 12 patients with positive symptoms also had
negative symptoms. Ten patients (50%) had clearly
migratory symptoms spreading smoothly from one body
part to another (e.g. from the hand, up the arm and into the
face). Patients were followed up for a mean of 568 days
(IQR 46–683 days). During this period, there were 2 sICH
(Fig. 1), and 1 ischaemic stroke. Both of the sICH occurred
in patients with ‘probable CAA’ (corresponding to an
annual sICH risk of 9% in patients with probable CAA),
neither of whom had experienced a previous ICH. There
were two deaths in our cohort during follow up (1 from
sICH; the other unrelated to sICH).
Systematic review and pooled analysis
Our systematic search terms yielded 2242 papers. After
reviewing these abstracts, 20 studies were eligible. Of
these, a further 12 were excluded (1 study did not have
cSAH as an inclusion criterion; 2 did not document which
patients had probable CAA; 4 did not provide average
(mean or median) follow-up; and 5 did not specify whether
sICH events occurred in those with probable CAA). Thus,
eight studies [10, 17, 20–28] of cSAH attributed to sus-
pected CAA were included in the meta-analysis, in addition
to our own cohort (see Fig. 2 for a flow chart of study
selection). The baseline characteristics of each of the
included studies are shown in Table 2. A total of 172
patients were included, 100 fulfilling criteria for probable
CAA and 72 not fulfilling criteria for probable CAA.
In a pooled analysis of all 172 patients with cSAH, the
absolute sICH event rate per patient-year for patients with
suspected CAA was 0.16 (95% CI 0.11–0.24). The pooled
absolute sICH event rate per patient-year for those with
probable CAA (n = 100) was 0.19 (95% CI 0.13–0.27);
there was little heterogeneity between studies (I2 = 31%)
(Fig. 3). For those not fulfilling criteria for probable CAA
(n = 72) the pooled event rate per patient-year was 0.07
(95% CI 0.03–0.15), with minimal heterogeneity
(I2 = 0%).
In a sensitivity analysis including a recently published
cohort of 27 survivors of lobar ICH attributed to CAA with
acute cSAH and available follow up [29] the results
remained similar, with a future risk of sICH per patient-
year of 0.17 (95% CI 0.12–0.25). This cohort was not
included in the main analysis as patients had both lobar
ICH and concurrent cSAH at presentation, so are different
to those in the other studies we included.
Discussion
In our hospital cohort study the risk of symptomatic ICH
following cSAH in patients with probable CAA was 4% per
year; this risk was unrelated to prior ICH, as only 2 of 20
patients (5%) had a history of prior ICH (and they did not
have a sICH during follow up). Most previous data sug-
gesting a high future sICH risk in patients with suspected
CAA (of around 9–16% per year [11, 30]) are from popu-
lations of patients who presented with ICH. In our pooled
analysis the annual risk of symptomatic ICH after cSAH due
to suspected CAA was similarly high, at 19% per year (95%
CI 13–27%) for patients with probable CAA, although
lower, at 7% (95% CI 3–15%), for patients who did not meet
the modified Boston criteria for probable CAA.
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We also found that those with cSAH nearly always had
cSS, with a high prevalence of disseminated cSS and
severe centrum semiovale MRI-visible perivascular spaces,
lobar CMBs and severe WMH (leukoaraiosis). The almost
universal presence of cSS (often disseminated) and high
risk of ICH following cSAH in our cohort is consistent with
evidence that siderosis-predominant CAA is a distinct
subtype, with a high risk of intracranial (and convexity
subarachnoid) haemorrhage compared to CAA with pre-
dominant CMBs or leukoaraiosis [31]. Notably, in our
cohort, the prevalence of cSS extending beyond that sec-
ondary to the index cSAH was higher than in typical CAA-
related ICH populations [32]. A recent study suggested that
active leptomeningeal CAA (with contrast enhancement) is
the likely cause of CAA-related cSS [27]. Thus, the high
prevalence of disseminated cSS in our cohort suggests
active and widespread leptomeningeal CAA, causing
repeated previous cSAH leading to cSS.
Although our study suggests that the risk of future sICH
is highest in patients who fulfil the Boston criteria for
probable CAA, it should be noted that eligibility for these
criteria can change over time; indeed, four of nine patients
with possible CAA or non-CAA who had subsequent ICH
at follow-up then ‘‘converted’’ to probable CAA, but were
Fig. 1 a Axial CT scan shows
acute cSAH in the right central
sulcus (white arrowheads);
b follow-up axial CT shows a
subsequent right frontal ICH in
the same patient as panel
(a) (white arrow); c axial CT
scan shows acute cSAH in a left
frontal lobe sulcus (white
arrowheads); d a follow-up
axial T2-weighted MRI shows
an acute left frontal ICH in the
same patient as panel (c) (white
arrow)
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still considered to be ‘‘non-probable CAA’’ for the purpose
of the pooled analysis.
The pooled event rate of 19% per year for future ICH in
patients with probable CAA is higher than the future risk of
ischaemic stroke reported after ICH, which has been
reported to be between 1.3 and 2.9% per year following
deep ICH and 2.5–14.3% per year following lobar ICH
[33]. Data on the risk of future ischaemic stroke following
cSAH is scarce [21, 28], but our findings suggest that the
risk of ICH is very likely to be greater than the risk of
cerebral ischaemia. This finding is potentially clinically
relevant when making decisions about antithrombotic drug
use. Although data are not available on whether or how
antithrombotic drug use might affect the future risk of
sICH or ischaemia in patients with cSAH at risk of future
vaso-occlusive events (e.g. those with atrial fibrillation or
other vascular risk factors), our findings suggest that
antithrombotic drugs might be best avoided after cSAH
unless there is a very compelling clinical indication. Since
the TFNE commonly associated with cSAH can closely
mimic the typical symptoms of TIA (although they are
more likely to be positive and of spreading onset) the
diagnosis of cSAH is crucial in patients with suspected
TIA. Although CT may detect cSAH, MRI might be
preferable because it is sensitive to small areas of sulcal
haemorrhage and can identify cortical superficial siderosis
and CMBs, allowing a more confident diagnosis of cSAH
related to CAA.
Our study has strengths. We used multiple overlapping
methods of case ascertainment to identify all patients with
cSAH presenting to our comprehensive stroke service. All
visual rating of neuroimaging was undertaken by a trained
PRISMA 2009 Flow Diagram
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observer blinded to outcome. Our systematic search fol-
lowed established PRISMA guidelines and pooled all
available studies using mixed effects Poisson regression to
account for studies with no ICH events.
Our study also has limitations. Despite conducting a
systematic search and pooling event rates in a meta-anal-
ysis, there were still few sICH events. Furthermore, as all
studies are hospital-based there is potential for significant
selection bias and detection bias (due to potentially selec-
tive follow up). We were unable to adjust for confounders
such as hypertension, age, antithrombotic treatment, pre-
vious ICH, which can all contribute to sICH risk. Follow-
up times were variable from study to study, but we did not
have access to the data needed for a time-to-event analysis.
We did not obtain individual patient data, and so were
unable to explore whether imaging findings such as cSS,
CMBs and leukoaraiosis modify the risk of ICH.
In summary, patients who present with an acute cSAH
and suspected CAA have a substantial risk of symp-
tomatic ICH (16% per patient-year overall). The future
sICH risk might be highest in those with neuroimaging
findings consistent with probable CAA. These estimates
of sICH event rates should be of value to clinicans when
counselling patients regarding their future risk, and
emphasise the importance of offering treatments aiming
to reduce this risk. We suggest that antithrombotic drugs
(antiplatelet and anticoagulant agents) are probably best
avoided wherever possible after proven cSAH, unless
there is a compelling indication, since the future sICH
risk is high, and likely to be increased by exposure to
such drugs. In patients with cSAH and a strong indica-
tion for antithrombotic drugs (e.g. recent symptomatic
ischaemic heart disease or peripheral vascular disease),
the likely benefits on reducing vaso-occlusive events
must be carefully weighed against the potential for
increasing the sICH risk. In patients with cSAH it seems
reasonable to reduce blood pressure, which is effective
for the long-term secondary prevention of ICH,
including that attributed to probable CAA [34]. Although
this data currently presents the best available evidence
the small sample sizes and limited information on other
risk factors remains a limitation; future prospective
studies with individual patient data might help consoli-
date our observations.
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